ArticleJournal of thoracic disease2026
Primary tumor surgical resection in multimodal treatment of stage IVA non-small cell lung cancer-comparison of resected and non-resected cases.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary tumor surgical resection for stage IVA non-small cell lung cancer (NSCLC) patients remains controversial in the current era of molecular targeted agents (MTAs) and immune checkpoint inhibitors (ICIs). Clinical impact and perioperative safety of primary tumor resection for stage IVA NSCLC patients undergoing multimodal treatment were analyzed. Methods: This was a retrospective review of stage IVA NSCLC patients (n=145) treated between 2011 and 2023 with (n=47) or without (n=98) primary tumor surgical resection. Propensity scores were estimated using clinical and demographic variables, with inverse probability of treatment weighting (IPTW) applied for adjusting treatment selection bias. Overall survival (OS) was analyzed using the Kaplan-Meier method and Cox proportional hazards model. Results: Patients with missing data were excluded, and the results of 45 surgical and 73 non-surgical patients were included in the IPTW-adjusted analysis. Prior to the adjustment, the median OS in the surgical group was 47.2 months compared with 17.2 months in the non-surgical group [hazard ratio (HR): 0.38, 95% confidence interval (CI): 0.23-0.62; P<0.001], while those after IPTW adjustment were 36.5 and 21.1 months, respectively (HR: 0.44, 95% CI: 0.23-0.85; P=0.01). Subgroup analyses indicated significant benefits for age <75 years, Eastern Cooperative Oncology Group performance status 0, tumor size ≤5 cm, T1-2, and N0-2 disease, regardless of MTA or ICI use. Surgical resection was safely performed with low complication rates and no surgery-related mortality. Conclusions: Primary tumor resection as part of multimodal treatment may be associated with improved survival in carefully selected stage IVA NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.